Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Boston Scientific

Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that is headquartered in Marlborough, Massachusetts and was founded in 1979 by John Abele and Pete Nicholas.

The company is interested in providing medical solutions for patients and to improve the health of patients around the world. The company holds medical specialties including electrophysiology, female pelvic medicine, gastroenterology, gynecology, interventional cardiology, interventional radiology and oncology, neurological surgery, orthopedic surgery, pain medicine, pulmonology, structural heart, urology, and vascular surgery.

The company looks to provide educational systems and programs to support healthcare professionals in the delivery of patient care worldwide. They offer procedural simulations and learning programs with globally-recognized faculty. They provide curriculums for their medical specialties. They also dedicate training centers around the world through institute for advancing science.

Timeline

April 16, 2019
In announcing its decision on Tuesday, the F.D.A. said that Boston Scientific and Coloplast, a Danish company, had not demonstrated a reasonable assurance of safety and effectiveness for the devices.
February 12, 2019
Boston Scientific launches AdVance XP male stress urinary incontinence sling - MassDevice
December 27, 2018
Boston Scientific acquires Millipede for $325m with an additional $125 million based on a commercial milestone.
November 2018
Boston Scientific agreed to offer roughly $4.24 billion to acquire BTG.
August 2018
Boston Scientific amends an existing $1 billion credit agreement to help fund the BTG acquisition.
January 2018
Boston Scientific initially invests $90 million into Millipede, with an option to acquire the remaining shares in the company for $325 million and an additional $125 million milestone payment.
2015
Boston Scientific moves to acquire the remote cardiac monitoring developer Preventice Solutions.
May 22, 2009
Boston Scientific raises a $30,000,000 series C round from Accuitive Medical Ventures, Boston Scientific, Finistere Ventures and ONSET Ventures.
October 23, 2006
Boston Scientific raises a $19,000,000 series B round from Boston Scientific and ONSET Ventures.
June 17, 2004
Boston Scientific raises a $9,000,000 series A round from ONSET Ventures.

Funding rounds

Acquisitions

Invested in

Patents

Funding Rounds Participated In

Further reading

Title
Author
Link
Type
Date

Boston Scientific and Osiris Therapeutics Announce Stem Cell Alliance: Alliance to develop and commercialize cardiovascular therapies using adult Mesenchymal Stem Cells | Osiris Therapeutics, Inc.

Osiris Therapeutics

Web

Documentaries, videos and podcasts

Title
Date
Link

Voices of Innovation - David Knapp

December 21, 2018

News

Title
Author
Date
Publisher
Description
Conor Hale
October 6, 2021
FierceBiotech
The Canadian company's specialty includes minimally invasive platforms that allow surgeons to accurately cross the thin, internal barrier separating the heart's upper right and left chambers.
Andrea Park
September 21, 2021
FierceBiotech
The deal will see Boston Scientific put down about $269 million up front to acquire Devoro, in which it has been a strategic investor since 2019. Down the line, it'll pay out up to another $67 million as its new subsidiary hits certain unspecified clinical and regulatory milestones.
Andrea Park
September 20, 2021
FierceBiotech
Boston Scientific's tumor-targeting glass microbeads continue to shatter expectations for cancer treatment. The newly released results of a long-term study showed adding TheraSpheres to a chemotherapy regimen can extend survival for patients with colorectal cancer that has spread to the liver.
FinSMEs
September 16, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Conor Hale
August 30, 2021
FierceBiotech
Both minimally invasive devices are designed to reduce the long-term risk of stroke in patients with atrial fibrillation.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.